J Korean Neuropsychiatr Assoc.  1997 Jul;36(4):732-741.

Combined Therapy of Paroxetine and Tricyclic Antidepressant in Depression of Schizophrenic Patients

Affiliations
  • 1Department of Psychiatry, School of Medicine and Institute of Neuroscience, Inje University, Pusan, Korea.

Abstract

Depression is well-known to comorbid with several psychiatric disorders. Many schizophrenics also suffer from depression in the course of their illness. Combined therapy of SSRI and tricyclic antidepressants were reported to have benefits in some depressed patients. Paroxetine, a potent CYP2D6 inhibitor, increases the blood levels of tricyclic antidepressant markedly, Using paroxetine, we tried this combined therapy in the treatment of depressive symptoms in 10 chronic schizophrenic inpatients and evaluated its efficacy and drug interactions between paroxetine and tricyclic antidepressants. The following results were obtained: 1) The mean score of Hamilton's Depression Rating Scale(HDRS) was reduced significantly after 6 weeks-trials of this combined therapy for the mild depressive symptoms in 10 chronic schizophrenics. In four patients, 50% or more reductions in the scores of HDRS were noticed at final evaluation. 2) Two among our 10 subjects experienced severe toxic behavioral problems. Anticholinergic crisis with toxic confusion due to high blood levels of tricyclics was fecund in one patient and the other showed rapid clinical deterioration in his psychotic symptoms such as delusion and hallucination without any consciousness alternation. 3) Baseline plasma levels of tricyclics before adding paroxetine were higher or than expected in our chronic schizophrenic subjects maintained with their antipsychotic medications. Several antipsychotics were also known as a potent CYF2D6 inhibitors and to increase the blood levels of tricyclics. Because the blood levels of tricyclics had already increased significantly by the use of antipsychotics, adding paroxetine to antipsychotics and tricyclic antidepressant In our subjects could increase the blood levels of tricyclics not so much as previously reported in the literatures.

Keyword

Schizophrenia; Depression; Faroxetine; Tricyclic antidepressant; Drug interaction

MeSH Terms

Antidepressive Agents, Tricyclic
Antipsychotic Agents
Consciousness
Cytochrome P-450 CYP2D6
Delusions
Depression*
Drug Interactions
Hallucinations
Humans
Inpatients
Paroxetine*
Plasma
Schizophrenia
Antidepressive Agents, Tricyclic
Antipsychotic Agents
Cytochrome P-450 CYP2D6
Paroxetine
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr